Cargando…
Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies
Hepatic fibrosis is caused by chronic injury due to toxic, infectious, or metabolic causes, and it may progress to cirrhosis and hepatocellular carcinoma. There is currently no antifibrotic therapy authorized for human use; however, there are promising studies using cell therapies. There are also no...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675604/ https://www.ncbi.nlm.nih.gov/pubmed/36411771 http://dx.doi.org/10.1155/2022/2841894 |
_version_ | 1784833411925409792 |
---|---|
author | Enciso, Nathaly Amiel, José Fabián-Domínguez, Fredy Pando, Jhon Rojas, Nancy Cisneros-Huamaní, Carlos Nava, Ernesto Enciso, Javier |
author_facet | Enciso, Nathaly Amiel, José Fabián-Domínguez, Fredy Pando, Jhon Rojas, Nancy Cisneros-Huamaní, Carlos Nava, Ernesto Enciso, Javier |
author_sort | Enciso, Nathaly |
collection | PubMed |
description | Hepatic fibrosis is caused by chronic injury due to toxic, infectious, or metabolic causes, and it may progress to cirrhosis and hepatocellular carcinoma. There is currently no antifibrotic therapy authorized for human use; however, there are promising studies using cell therapies. There are also no animal models that exactly reproduce human liver fibrosis that can be used to better understand the mechanisms of its regression and identify new targets for treatment and therapeutic approaches. On the other hand, mesenchymal stem cells (MSC) have experimentally demonstrated fibrosis regression effects, but it is necessary to have an animal model of advanced liver fibrosis to evaluate the effect of these cells. The aim of this work was to establish a protocol for the induction of advanced liver fibrosis in rats using thioacetamide (TAA), which will allow us to perform trials using MSC as a possible therapy for fibrosis regression. For this purpose, we selected 24 female rats and grouped them into three experimental groups: the control group (G-I) without treatment and groups II (G-II) and III (G-III) that received TAA by intraperitoneal injection for 24 weeks. Then, 1 × 106/kg adipose mesenchymal stem cells (ASCs) were infused intravenously. Groups G-I and G-II were sacrificed 7 days after the last dose of ASC, and G-III was sacrificed 8 weeks after the last ASC infusion, all with xylazine/ketamine (40 mg/kg). The protocol used in this work established a model of advanced hepatic fibrosis as corroborated by METAVIR tests of the histological lesions; by the high levels of the markers α-SMA, CD68, and collagen type I; by functional alterations due to elevated markers of the hepatic lesions; and by alterations of the leukocytes, lymphocytes, and platelets. Finally, transplanted cells in the fibrous liver were detected. We conclude that TAA applied using the protocol introduced in this study induces a good model of advanced liver fibrosis in rats. |
format | Online Article Text |
id | pubmed-9675604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-96756042022-11-20 Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies Enciso, Nathaly Amiel, José Fabián-Domínguez, Fredy Pando, Jhon Rojas, Nancy Cisneros-Huamaní, Carlos Nava, Ernesto Enciso, Javier Anal Cell Pathol (Amst) Research Article Hepatic fibrosis is caused by chronic injury due to toxic, infectious, or metabolic causes, and it may progress to cirrhosis and hepatocellular carcinoma. There is currently no antifibrotic therapy authorized for human use; however, there are promising studies using cell therapies. There are also no animal models that exactly reproduce human liver fibrosis that can be used to better understand the mechanisms of its regression and identify new targets for treatment and therapeutic approaches. On the other hand, mesenchymal stem cells (MSC) have experimentally demonstrated fibrosis regression effects, but it is necessary to have an animal model of advanced liver fibrosis to evaluate the effect of these cells. The aim of this work was to establish a protocol for the induction of advanced liver fibrosis in rats using thioacetamide (TAA), which will allow us to perform trials using MSC as a possible therapy for fibrosis regression. For this purpose, we selected 24 female rats and grouped them into three experimental groups: the control group (G-I) without treatment and groups II (G-II) and III (G-III) that received TAA by intraperitoneal injection for 24 weeks. Then, 1 × 106/kg adipose mesenchymal stem cells (ASCs) were infused intravenously. Groups G-I and G-II were sacrificed 7 days after the last dose of ASC, and G-III was sacrificed 8 weeks after the last ASC infusion, all with xylazine/ketamine (40 mg/kg). The protocol used in this work established a model of advanced hepatic fibrosis as corroborated by METAVIR tests of the histological lesions; by the high levels of the markers α-SMA, CD68, and collagen type I; by functional alterations due to elevated markers of the hepatic lesions; and by alterations of the leukocytes, lymphocytes, and platelets. Finally, transplanted cells in the fibrous liver were detected. We conclude that TAA applied using the protocol introduced in this study induces a good model of advanced liver fibrosis in rats. Hindawi 2022-11-12 /pmc/articles/PMC9675604/ /pubmed/36411771 http://dx.doi.org/10.1155/2022/2841894 Text en Copyright © 2022 Nathaly Enciso et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Enciso, Nathaly Amiel, José Fabián-Domínguez, Fredy Pando, Jhon Rojas, Nancy Cisneros-Huamaní, Carlos Nava, Ernesto Enciso, Javier Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies |
title | Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies |
title_full | Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies |
title_fullStr | Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies |
title_full_unstemmed | Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies |
title_short | Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies |
title_sort | model of liver fibrosis induction by thioacetamide in rats for regenerative therapy studies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675604/ https://www.ncbi.nlm.nih.gov/pubmed/36411771 http://dx.doi.org/10.1155/2022/2841894 |
work_keys_str_mv | AT encisonathaly modelofliverfibrosisinductionbythioacetamideinratsforregenerativetherapystudies AT amieljose modelofliverfibrosisinductionbythioacetamideinratsforregenerativetherapystudies AT fabiandominguezfredy modelofliverfibrosisinductionbythioacetamideinratsforregenerativetherapystudies AT pandojhon modelofliverfibrosisinductionbythioacetamideinratsforregenerativetherapystudies AT rojasnancy modelofliverfibrosisinductionbythioacetamideinratsforregenerativetherapystudies AT cisneroshuamanicarlos modelofliverfibrosisinductionbythioacetamideinratsforregenerativetherapystudies AT navaernesto modelofliverfibrosisinductionbythioacetamideinratsforregenerativetherapystudies AT encisojavier modelofliverfibrosisinductionbythioacetamideinratsforregenerativetherapystudies |